Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
nicotinic acid/obezita
Odkaz sa uloží do schránky
Strana 1 od 100 výsledky
Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Inclusion of stochastic differential equations in mixed effects models provides means to quantify and distinguish three sources of variability in data. In addition to the two commonly encountered sources, measurement error and interindividual variability, we also consider uncertainty in the
Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
This study investigates the impact of disease on nicotinic acid (NiAc)-induced changes in plasma concentrations of non-esterified fatty acids (NEFA). NiAc was given by constant intravenous infusion to normal Sprague-Dawley and obese Zucker rats, and arterial blood samples were taken for analysis of
Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover in normal Sprague-Dawley and obese Zucker rats in order to perform a joint PKPD of data from more than 100 normal Sprague-Dawley and obese Zucker rats, exposed to several administration routes and
Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
OBJECTIVE
Nicotinic acid (NA) treatment decreases plasma triglycerides and increases HDL cholesterol, but the mechanisms involved in these change are not fully understood. A reduction in cholesteryl ester transfer protein (CETP) activity has been advanced to explain most lipid-modulating effects of
Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Apolipoprotein B100 (apoB100) is an essential component of very low density lipoprotein (VLDL) and low-density lipoprotein (LDL), both independent markers of cardiovascular risk. Nicotinic acid (NA) is an efficacious drug for decreasing VLDL and LDL, but the underlying mechanisms are unclear. For
Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Nicotinic acid (NiAc) is a potent inhibitor of lipolysis, acutely reducing plasma free fatty acid (FFA) concentrations. However, a major FFA rebound is seen during rapid NiAc washout, and sustained exposure is associated with tolerance development, with FFAs returning to pretreatment levels. Our aim
[Effect of nicotinic acid and adrenaline on plasmatic concentration of NEFA and blood sugar in obese children].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
[Effects of nicotinic acid on the secretion of HGH in normal and obese subjects].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
[Effect of nicotinic acid on metabolic phenomena caused by anaerobic work in obese subjects].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Metabolic changes induced by a nicotinic acid derivative in patients with obesity grades 1, 2 and 3.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Effect of nicotinic acid administaation on plasma HGH, FFA and glucose in obese subjects and in hypopituitary patients.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Trigonelline (TRG) and nicotinic acid (NA), in which the former but not the latter improved the blood glucose level in the oral glucose tolerance test (OGTT) in Goto-Kakizaki (GK) rats were tested for anti-diabetic effects in mellitus models of KK-A(y) obese mice that had type 2 diabetes. Blood
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
In the field of dyslipidemia and metabolic syndrome, four innovative therapies are reviewed: Ezetimibe (Ezétrol) is a selective cholesterol absorption inhibitor. Co-administration of ezetimibe with low dose of statins shows LDL lowering comparable to that of the highest dose of the respective statin
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
NEFAs characteristically are elevated in obese NIDDM patients in both the basal state and after insulin. This elevation might aggravate glycemic control both by decreasing peripheral glucose disposal (glucose-fatty acid cycle), and by increasing HGO. Thus, lowering plasma NEFA levels might improve
Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described.
METHODS
Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2g/day extended-release nicotinic acid (ERN), 4g/day
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
